CTOs on the Move

Triumvira

www.triumvira.com

 
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Donna Rill
Chief Technology Officer Profile

Funding

Triumvira raised $55M on 08/27/2020

Similar Companies

Pharm Agra Labs

Pharm Agra Labs is a Brevard, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunomic Therapuetics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.

Gradalis

Gradalis, Inc. is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of drugs, vaccines, tools, and diagnostics primarily in the area of cancer. Gradalis has its own GMP manufacturing facility along with highly skilled technical leadership and staff and a strategic partnership with Mary Crowley Cancer Research Centers for clinical development of Gradalis products. The Company has two primary platforms, one centered on personalized autologous vaccines and a second focused on bifunctional short hairpin RNA (shRNA) to enable specific protein knockdown. In addition. Gradalis has numerous partnerships and joint ventures that provide it with access to other cutting edge clinical and pre-clinical stage programs.  

Janpix

Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.

Micropoint Bioscience

Micropoint Bioscience is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.